The MInimizing RIsk of CLotting Events Trial
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07930429. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Optimizing the Implementation of Personalized Risk-prediction Models for Venous Thromboembolism Among Hospitalized Adults: The MInimizing RIsk of CLotting Events (MIRICLE) Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to evaluate whether the implementation of a real-time prognostic model can effectively identify and prevent blood clots among hospitalized patients. The main questions it aims to answer is: 1. Can the prognostic model reduce rates of hospital-acquired blood clots (also known as hospital-acquired venous thromboembolisms)? 2. Is the prognostic model an effective tool for initiating timely and appropriate preventive treatment (i.e., thromboprophylaxis)? Researchers will compare the intervention arm with the control arm (standard of care) to determine whether the intervention reduces rates of blood clots and improves initiation of preventive treatment. The intervention (clinical decision support that displays the prognostic model's output) will be implemented by displaying a risk score in clinicians' workflow in the electronic health record (EHR) to notify clinicians of patients who are at higher risk for sustaining a blood clot. The intervention will not dictate patient care and clinicians will continue to use their clinical knowledge and judgment in their clinical decision-making.
Study identification
- NCT ID
- NCT07930429
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 65,000 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2026 (Estimated)
- Primary completion
- Jun 2028 (Estimated)
- Completion
- Jun 2028 (Estimated)
- Last update posted
- Nov 12, 2026
2026 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Vanderbilt Adult Hospital | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07930429, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 12, 2026 · Synced Nov 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.